{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:01:11Z","timestamp":1792144871461,"version":"4.4.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"vor","delay-in-days":40,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.cgh.2026.06.003","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:14:24Z","timestamp":1781136864000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Risk of Lymphoma Associated With Biologics and Immunosuppressants in Inflammatory Bowel Disease Patients: A Nationwide Nested Case-Control Study"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1156-9289","authenticated-orcid":false,"given":"Antoine","family":"Meyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Weill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Carbonnel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Dray-Spira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2026.06.003_bib1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1080\/00365521.2025.2491013","article-title":"Global prevalence of biologic drugs use in inflammatory bowel diseases: a systematic review and meta-analysis","volume":"60","author":"Tianeze De Castro","year":"2025","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cgh.2026.06.003_bib2","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2026.06.003_bib3","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2026.06.003_bib4","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/apt.16050","article-title":"Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and\/or thiopurines in patients with inflammatory bowel disease","volume":"52","author":"Chupin","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2026.06.003_bib5","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/aje\/kws375","article-title":"Use of azathioprine and the risk of cancer in inflammatory bowel disease","volume":"177","author":"Pasternak","year":"2013","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.cgh.2026.06.003_bib6","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/ecco-jcc\/jjz137","article-title":"The safety profile of vedolizumab in ulcerative colitis and Crohn\u2019s disease: 4 years of global post-marketing data","volume":"14","author":"Cohen","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2026.06.003_bib7","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41598-024-75421-1","article-title":"Data mining and analysis of adverse events of Vedolizumab based on the FAERS database","volume":"15","author":"Xu","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.cgh.2026.06.003_bib8","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/ecco-jcc\/jjae013","article-title":"Safety of ustekinumab in inflammatory bowel disease: pooled safety analysis through 5 years in Crohn\u2019s disease and 4 years in ulcerative colitis","volume":"18","author":"Ghosh","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2026.06.003_bib9","first-page":"706","article-title":"Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR)","volume":"14","author":"Papp","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.cgh.2026.06.003_bib10","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1136\/ard-2023-224049","article-title":"JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications","volume":"82","author":"Russell","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2026.06.003_bib11","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/annrheumdis-2014-205847","article-title":"Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2026.06.003_bib12","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.14309\/ajg.0000000000003670","article-title":"Patients included in clinical trials of biological drugs for inflammatory bowel disease do not represent the real-world population","volume":"121","author":"Casas Deza","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2026.06.003_bib13","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2026.06.003_bib14","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1093\/ije\/dys147","article-title":"Case-control studies: basic concepts","volume":"41","author":"Vandenbroucke","year":"2012","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.cgh.2026.06.003_bib15","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/MLR.0000000000000471","article-title":"The best use of the charlson comorbidity index with electronic health care database to predict mortality","volume":"54","author":"Bannay","year":"2016","journal-title":"Med Care"},{"key":"10.1016\/j.cgh.2026.06.003_bib16","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1007\/s11606-013-2755-z","article-title":"Six persistent research misconceptions","volume":"29","author":"Rothman","year":"2014","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.cgh.2026.06.003_bib17","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjaf091","article-title":"Cancer incidence in patients with ulcerative colitis na\u00efve to or treated with thiopurine and targeted therapies\u2014a cohort study 2007 to 2022 with comparison to the general population","volume":"19","author":"Everhov","year":"2025","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2026.06.003_bib18","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/MIB.0000000000000457","article-title":"Risk of lymphoma, colorectal and skin cancer in patients with IBD treated with immunomodulators and biologics: a Quebec claims database study","volume":"21","author":"Kopylov","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2026.06.003_bib19","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.cgh.2024.08.006","article-title":"Thiopurines and the risk of cancer in patients with inflammatory bowel disease and reference individuals without inflammatory bowel disease: a Danish nationwide cohort study (1996-2018)","volume":"23","author":"Wewer","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.06.003_bib20","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.cgh.2020.02.009","article-title":"Predicting, preventing, and managing treatment-related complications in patients with inflammatory bowel diseases","volume":"18","author":"Beaugerie","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.06.003_bib21","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.3748\/wjg.v23.i18.3240","article-title":"Thiopurine use associated with reduced B and natural killer cells in inflammatory bowel disease","volume":"23","author":"Lord","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cgh.2026.06.003_bib22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/bmb\/ldl020","article-title":"Thiopurines, DNA damage, DNA repair and therapy-related cancer","volume":"79-80","author":"Karran","year":"2006","journal-title":"Br Med Bull"},{"key":"10.1016\/j.cgh.2026.06.003_bib23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jaut.2017.02.001","article-title":"Impact of anti-TNF therapy on NK cells function and on immunosurveillance against B-cell lymphomas","volume":"80","author":"Nocturne","year":"2017","journal-title":"J Autoimmun"},{"key":"10.1016\/j.cgh.2026.06.003_bib24","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/ibd\/izaa065","article-title":"Propagation of EBV-driven lymphomatous transformation of peripheral blood B cells by immunomodulators and biologics used in the treatment of inflammatory bowel disease","volume":"26","author":"Levhar","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2026.06.003_bib25","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semcancer.2013.12.001","article-title":"Lymphoma development in patients with autoimmune and inflammatory disorders\u2013what are the driving forces?","volume":"24","author":"Baecklund","year":"2014","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.cgh.2026.06.003_bib26","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1016\/j.cgh.2023.04.001","article-title":"Increasing risk of lymphoma over time in Crohn\u2019s disease but not in ulcerative colitis: a Scandinavian cohort study","volume":"21","author":"Ol\u00e9n","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.06.003_bib27","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S2468-1253(24)00034-7","article-title":"A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn\u2019s disease (PROFILE)","volume":"9","author":"Noor","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.06.003_bib28","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41572-020-0189-6","article-title":"Hodgkin lymphoma","volume":"6","author":"Connors","year":"2020","journal-title":"Nat Rev Dis Primers"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356526004131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356526004131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T19:28:22Z","timestamp":1783798102000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356526004131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":28,"alternative-id":["S1542356526004131"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2026.06.003","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of Lymphoma Associated With Biologics and Immunosuppressants in Inflammatory Bowel Disease Patients: A Nationwide Nested Case-Control Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2026.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Gastroenterological Association Institute.","name":"copyright","label":"Copyright"}]}}